[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2003256601B2 - 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors - Google Patents

6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors Download PDF

Info

Publication number
AU2003256601B2
AU2003256601B2 AU2003256601A AU2003256601A AU2003256601B2 AU 2003256601 B2 AU2003256601 B2 AU 2003256601B2 AU 2003256601 A AU2003256601 A AU 2003256601A AU 2003256601 A AU2003256601 A AU 2003256601A AU 2003256601 B2 AU2003256601 B2 AU 2003256601B2
Authority
AU
Australia
Prior art keywords
substituted
alkyl
unsubstituted
carbon atoms
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003256601A
Other versions
AU2003256601A1 (en
Inventor
Allan T. Hopper
Richard A. Schumacher
Ashok Tehim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Publication of AU2003256601A1 publication Critical patent/AU2003256601A1/en
Application granted granted Critical
Publication of AU2003256601B2 publication Critical patent/AU2003256601B2/en
Priority to AU2010200233A priority Critical patent/AU2010200233A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs. The compounds of the present invention are of Formulas I and II: wherein R1, R2, R3, R4, R7 and R8 are as defined herein.

Description

P\WPDOCS\DH1MSPECl\l 2513301 M -nory 1sSPAdoc.-8/09f2009 6-AMINO-1H-INDAZOLE AND 4-AMINOBENZOFURAN COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS Field Of The Invention The present invention relates generally to the field of phosphodiesterase 4 (PDE4) enzyme inhibition. More specifically this invention relates to selective PDE4 inhibition by novel compounds, e. g. , aminoindazole and aminobenzofuran analogs, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. Background Of The Invention The cyclic nucleotide specific phosphodiesterases (PDEs) represent a family of enzymes that catalyze the hydrolysis of various cyclic nucleoside monophosphates (including cAMP and cGMP). These cyclic nucleotides act as second messengers within cells, and as messengers, carry impulses from cell surface receptors having bound various hormones and neurotransmitters. PDEs act to regulate the level of cyclic nucleotides within cells and maintain cyclic nucleotide homeostasis by degrading such cyclic mononucleotides resulting in termination of their messenger role.
WO 2004/009557 PCT/US2003/022401 PDE enzymes can be grouped into eleven families according to their specificity toward hydrolysis of cAMP or cGMP, their sensitivity to regulation by calcium, calmodulin or cGMP, and their selective inhibition by various compounds. For example, PDE 1 is stimulated by Ca 2 +/calmodulin. PDE 2 is cGMP-dependent, and is found in the heart and adrenals. PDE 3 is cGMP-dependent, and inhibition of this enzyme creates positive inotropic activity. PDE 4 is cAMP specific, and its inhibition causes airway relaxation, antiinflammatory and antidepressant activity. PDE 5 appears to be important in regulating cGMP content in vascular smooth muscle, and therefore PDE 5 inhibitors may have cardiovascular activity. Since the PDEs possess distinct biochemical properties, it is likely that they are subject to a variety of different forms of regulation. PDE4 is distinguished by various kinetic properties including low Michaelis constant for cAMP and sensitivity to certain drugs. The PDE4 enzyme family consists of four genes, which produce 4 isoforms of the PDE4 enzyme designated PDE4A, PDE4B, PDE4C, and PDE4D [See: Wang et al., Expression, Purification, and Characterization of human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D, Biochem. Biophys. Res. Comm., 234, 320 324 (1997)] In addition, various splice variants of each PDE4 isoform have been identified. PDE4 isoenzymes are localized in the cytosol of cells and are unassociated with any known membranous structures. PDE4 isoenzymes specifically inactivate cAMP by catalyzing its hydrolysis to adenosine 5'-monophosphate (AMP). Regulation of cAMP activity is important in many biological processes, including inflammation and memory. Inhibitors of PDE4 isoenzymes such as rolipram, piclamilast, CDP-840 and ariflo are powerful antiinflannatory agents and therefore may be useful in treating diseases where inflammation is problematic such as asthma or arthritis. Further, rolipram improves the cognitive performance of rats and mice in learning paradigms. 2 WO 2004/009557 PCT/US2003/022401 O C1 o0 N0 H C rolipram piclamilast In addition to such compounds as rolipram, xanthine derivatives such as pentoxifylline, denbufylline, and theophylline inhibit PDE4 and have received considerable attention of late for their cognition enhancing effects. cAMP and cGMP are second messengers that mediate cellular responses to many different hormones and neurotransmitters. Thus, therapeutically significant effects may result from PDE inhibition and the resulting increase in intracellular cAMP or cGMP in key cells, such as those located in the nervous system and elsewhere in the body. Rolipram, previously in development as an anti-depressant, selectively inhibits the PDE4 enzyme and has become a standard agent in the classification of PDE enzyme subtypes. Early work in the PDE4 field focused on depression and inflammation, and has subsequently been extended to include indications such as dementia. [see "The PDE IV Family Of Calcium Phosphodiesterases Enzymes," John A. Lowe, III, et al., Drugs of the Future 1992, 17(9):799 807 for a general review). Further clinical developments of rolipram and other first-generation PDE4 inhibitors were terminated due to the side effect profile of these compounds. The primary side effect in primates is emesis, while the primary side effects in rodents are testicular degranulation, weakening of vascular smooth muscle, psychotrophic effects, increased gastric acid secretion and stomach erosion. 3 P:WPDOCS\DK SPEClIl2513301 Mcory s.SPAdoc. 8/09/2009 SUMMARY OF THE INVENTION Disclosed herein are novel compounds, e. g. , aminoindazole and aminobenzofuran analogs, that inhibit PDE4 enzymes, and especially have improved side effect profiles, e. g. , are relatively non-emetic, (e. g. , as compared to the previously discussed prior art compounds). Preferably, the compounds selectively inhibit PDE4 enzymes. The compounds of this invention at the same time facilitate entry into cells, especially cells of the nervous system. Also disclosed herein are methods for synthesizing compounds with such activity and selectivity as well as methods of (and corresponding pharmaceutical compositions for) treating a patient, e. g. , mammals, including humans, requiring PDE inhibition, especially PDE4 inhibition, for a disease state that involves elevated intracellular PDE 4 levels or decreased cAMP levels, e. g. , involving neurological syndromes, especially those states associated with memory impairment, most especially long term memory impairment, as where such memory impairment is due in part to catabolism of intracellular cAMP levels by PDE 4 enzymes, or where such memory impairment may be improved by effectively inhibiting PDE4 enzyme activity. In a preferred aspect, the compounds of the invention improve such diseases by inhibiting PDE4 enzymes at doses which do not induce emesis. In a first aspect the present invention provides a compound of the formula II: R7 14 R Ra wherein R 3 is H, 4 P.\WPDOCS\DHIT\SPECI\I2513301 Memory IstSPAdoc-18/09/2009 alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, CI- 4 -alkoxy, or combinations thereof, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion which is branched or unbranched has I to 5 carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, Cj 4 -alkoxy, cyano or combinations thereof, arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has I to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, or heterocycle-alkyl group, wherein the heterocyclic portion may be aromatic, or partially or fully saturated and has 5 to 10 ring atoms in which at least I ring atom is a N, 0 or S atom, the alkyl portion, which is branched or unbranched, has I to 5 carbon atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof; R4 is H, aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 , amino, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, 2( heterocycle)tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 -L-, or combinations thereof, or 4a P:\WPDOCS\DHfSPECI\I253301 Me y IsiSPA doc-I&109/2009 heteroaryl having 5 to 10 ring atoms in which at least I ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 -L-, or combinations thereof, R5 is H, alkyl having I to 8 carbon atoms, which is unsubstituted or substituted one or more times with halogen, Ci- 4 -alkyl, CI- 4 -alkoxy, oxo, or combinations thereof, alkylamino or dialkylamino wherein each alkyl portion has independently I to 8 carbon atoms, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion has I to 5 carbon atoms, which is unsubstituted or substituted, preferably in the carbocyclic portion, one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having I to 4 carbon atoms, or combinations thereof, cycloalkylalkyl having 4 to 16 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, alkyl, alkoxy or combinations thereof, aryl having 6 to 14 carbon atoms which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or combinations thereof, arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has I to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, amino, 4b P\WPDOCSDfT\SPECI\I251330I Me y IsSPAdc-1809/2009 alkylamino, dialkylamino, or combinations thereof, and/or substituted in the alkyl portion by halogen, cyano, methyl, or combinations thereof, a heterocyclic group, which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least I ring atom is a N, 0 or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof, or a heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least I ring atom is a N, 0 or S atom, and the alkyl portion which is branched or unbranched and has I to 5 carbon atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof; L is a single bond or a divalent aliphatic radical having up to 8 carbon atoms wherein one or more -CH 2 - groups are each optionally replaced by -0-, -S-, -S02-, -SO-,
-NR
6 -, -SO 2 NH-, -NHSO 2 -, -CO-, -NR 6 CO-, -CONR 6 -, -NHCONH-, -OCONH-, -NHCOO-, -SCONH-, -SCSNH-, or -NHCSNH-; and R is H, or alkyl having I to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, CI- 4 -alkyl, C 1
-
4 alkoxy, oxo, or combinations thereof;
R
7 is alkoxy or alkylthio, in each case having I to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, R8 is -CO-CI.4-alkyl which is branched or unbranched and where the alkyl is unsubstituted or substituted one or more times by halogen, or is 4c P3WPDOCS\DImSPECI\12513301 M oy sSPA doc-1809/2009 Y A
R
9 X or Y-R 1 --7< 11
R
9 X-R
R
9 is H or alkyl having 1 to 4 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen, Rio is alkyl having I to 6 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen, R"1 is alkyl having I to 6 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen, X and Y are each independently 0 or S, and A is alkylene having 2 to 7 carbon atoms which is unsubstituted or substituted one or more times by halogen; wherein at least one of R 3 and R 4 is other than H; or a pharmaceutically acceptable salt thereof; wherein an optically active compound can be in the form of one of its separate enantiomers or mixtures thereof, including racemic mixtures. In a second aspect the present invention provides a pharmaceutical composition comprising a compound of the first aspect and a pharmaceutically acceptable carrier. In a third aspect the present invention provides a method for effecting PDE4 enzyme inhibition, enhancing cognition and/or treating psychosis in a patient comprising administering to said patient an effective amount of a compound according to the first aspect. 4d P:\WPDOCS\DMSPEC1\l2513301 Mcmory IstSPA do-18/09/2009 In a fourth aspect the present invention provides a method for treating a patient having a disease involving decreased cAMP levels comprising administering to said patient an effective amount of a compound according to the first aspect. In a fifth aspect the present invention provides a method of treating a patient suffering from an allergic or inflammatory disease comprising administering to said patient an effective amount of a compound according to the first aspect. In a sixth aspect the present invention provides a method of treating a patient suffering from neurodegeneration resulting from a disease or injury comprising administering to said patient an effective amount of a compound according to the first aspect. In a seventh aspect the present invention provides method of treating a patient suffering from drug addiction or morphine dependence comprising administering to said patient an effective amount of a compound according to the first aspect. In an eighth aspect the present invention provides use of a compound according to the first aspect, in the manufacture of a medicament for effecting PDE4 enzyme inhibition, enhancing cognition and/or treating psychosis. In a ninth aspect the present invention provides use of a compound according to the first aspect, in the manufacture of a medicament for treating a patient having a disease involving decreased cAMP levels. In a tenth aspect the present invention provides use of a compound according to the first aspect, in the manufacture of a medicament for treating a patient suffering from an allergic or inflammatory disease. In an eleventh aspect the present invention provides use of a compound according to the first aspect, in the manufacture of a medicament for treating a patient suffering from neurodegeneration resulting from a disease or injury. 4e P:\WPDOCS\DHT1SPEC\12513301 Mmory WsSPA doc-18/09/2009 In a twelfth aspect the present invention provides use of a compound according to the first aspect, in the manufacture of a medicament for treating a patient suffering from drug addiction or morphine dependence. The present invention includes compounds of Formulas I and II: 4f WO 2004/009557 PCT/US2003/022401 R 2 Nj 3 N R R3 11 1 O N R4 4 R 8 II wherein
R
1 is H, alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, or combinations thereof (e.g., cyclopentyl), or a heterocyclic group, which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, 0 or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalloxy dialkylamino, hydroxyalkyl (eg., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof (e.g., tetrahydrofuranyl, pyridyl, thienyl, pyrazinyl, quinolinyl, isoquinolinyl, pyrimidinyl, imidazolyl, thiazolyl, etc.), 5 WO 2004/009557 PCT/US2003/022401 R2 is H, or alkyl having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, cyano, and/or C1- 4 -alkoxy (e.g., CH 3 , C 2
H
5 , CHF 2 , CF 3 , etc.), and one or more -CH 2
CH
2 - groups can be replaced in each case by -CH=CH- or -C C-, is H, alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, CI- 4 -alkoxy, or combinations thereof (e.g., methyl, ethyl, propyl, etc.), a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion which is branched or unbranched has 1 to 5 carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, C1- 4 -alkoxy, cyano or combinations thereof (e.g., cyclohexenylmethyl, etc.), arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl (e.g., benzyl, phenethyl, phenpropyl, methylbenzyl, methoxybenzyl, trfluoromethyl, benzyl, methylenedioxobenzyl, etc.), or 6 WO 2004/009557 PCT/US2003/022401 heteroarylalkyl group, wherein the heteroaryl portion may be partially or fully saturated and has 5 to 10 ring atoms in which at least 1 ring atom is a N, 0 or S atom, the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, the heteroarylalkyl group is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof (e.g., pyridylmethyl, pyridylpropyl, methylpyridylmethyl, chloropyridyhnethyl, dichloropyridyhnethyl, thienylmethyl, thiazolylmethyl, quinolinylmethyl, isoquinolinylmethyl, piperidinylmethyl, furanylmethyl, imidazolylmethyl, methylimidazolylmethyl, pyrrolylmethyl, etc.); R4 is H, aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 , amino, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (eg., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, 2( heterocycle)tetrazole-5-yl (eg., 2-(2-tetrahydropyranyl)tetrazole-5-yl), hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy (eg. tert butyldimethylsilyloxy), R-L-, or combinations thereof (e.g., substituted or unsubstituted phenyl, naphthyl, and biphenyl, such as phenyl, methylphenyl, chlorophenyl, fluorophenyl, vinylphenyl, cyanophenyl, methylenedioxophenyl, ethylphenyl, dichlorophenyl, carboxyphenyl, ethoxycarbonylphenyl, dimethylphenyl, hydroxymethylphenyl, nitrophenyl, aminophenyl, etc.), or 7 WO 2004/009557 PCT/US2003/022401 heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (eg., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy (eg. tert-butyldimethylsilyloxy), R -L-, or combinations thereof (e.g., pyridyl, thienyl, pyrazinyl, quinolinyl, isoquinolinyl, pyrimidinyl, imidazolyl, thiazolyl, etc.); R" is H, alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times with halogen, CI- 4 -alkyl, C1- 4 -alkoxy, oxo, or combinations thereof (e.g., methyl, ethyl, propyl, etc.), alkylamino or dialkylamino wherein each alkyl portion has independently 1 to 8, preferably 1 to 4 carbon atoms (e.g., dimethylamino, etc.), a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion has 1 to 5 carbon atoms, which is unsubstituted or substituted, preferably in the carbocyclic portion, one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof (e.g., cyclohexenylmethyl, etc.), cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having 1 to 4 carbon atoms, or combinations thereof (e.g., cyclopentyl), 8 WO 2004/009557 PCT/US2003/022401 cycloalkylalkyl having 4 to 16, preferably 4 to 12 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, alkyl, alkoxy or combinations thereof (e.g., cyclopentylmethyl, cyclopropyhnethyl, etc.), aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (eg., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, (e.g., substituted or unsubstituted phenyl and naphthyl, methylphenyl, chlorophenyl, fluorophenyl, vinylphenyl, cyanophenyl, methylenedioxophenyl, ethylphenyl, dichlorophenyl, carboxyphenyl, ethoxycarbonylphenyl, dimethylphenyl, hydroxymethylphenyl, nitrophenyl, aminophenyl, etc.), arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, amino, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl (e.g., benzyl, phenethyl, phenpropyl, methylbenzyl, methoxybenzyl, trfluoromethyl, benzyl, methylenedioxobenzyl, etc.), a heterocyclic group, which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, 0 or S atom, which is unsubstituted or 9 WO 2004/009557 PCT/US2003/022401 substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (eg., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof (e.g., pyridyl, thienyl, pyrazinyl, quinolinyl, isoquinolinyl, pyrimidinyl, imidazolyl, thiazolyl, etc.), or a heterocycle-alkyl group, wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, o or S atom, and the alkyl portion which is branched or unbranched and has 1 to 5 carbon atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof (e.g., pyridylmethyl, pyridylpropyl, methylpridylmethyl, etc.); L is a single bond or a divalent aliphatic radical having up to 8 carbon atoms wherein one or more -CH 2 - groups are each optionally replaced by -0-, -8-, -So 2 -, -SO-, -NR 6 -,
SO
2 NH-, -NHSO 2 -, -CO-, -NR'CO-, -CONR 6 -, -NHCONH-, -OCONH, -NHCOO-, SCONH-, -SCSNH-, or -NHCSNH- (e.g.,-O-, CH 2 -, -CO-, -CO-O-, -O-CO-, -CO-NH-, NH-CO-, -CH 2
CH
2
CH
2 -NH-CO-, -CH 2
-CH
2 -0-, -S0 2
-NH-CH
2
CH
2 -0-, -O-CH 2
CH
2 -0-,
-CH
2 -NH-CO-, -CO-NH-CH 2 -, -S0 2 -NH-, -CH 2
-NH-SO
2 -, -CH 2
CH
2
CH
2
-SO
2 -NH-, CONHS0 2 -, etc.); R' is H, 10 WO 2004/009557 PCT/US2003/022401 alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, CI- 4 -alkyl, C 1
-
4 alkoxy, oxo, or combinations thereof (e.g., methyl, ethyl, propyl, etc.); R7 is alkoxy or alkylthio, in each case having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen (e.g.,
CH
3 , CHF 2 , CF 3 , etc.), R is -CO-C1..
4 -alkyl which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF 3 , etc.), or is Y\ /A
R
9 X or - x 11
R
9 X-R R9 is H or alkyl having 1 to 4 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF 3 , etc.), Rio is alkyl having 1 to 6 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF 3 , etc.), R" is-alkyl having 1 to 6 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF 3 , etc.), X and Y are each independently 0 or S, and A is alkylene having 2 to 7 carbon atoms which is unsubstituted or substituted one or more times by halogen; wherein in Formula I both of R 3 and R 4 are other than H and in Formula II at least one of
R
3 and R 4 is other than H; and 11 WO 2004/009557 PCT/US2003/022401 pharmaceutically acceptable salts thereof. According to a further aspect of the invention there is provided a genus of novel compounds according to the formulas III and IV: R7R 7 R o NH R 14 N R H llR IV wherein R1, R2, R3, R 4 , R 7 and R8 are as defined above. The compounds of this subgenus of Formulae I and II not only have PDE4 inhibitory activity, but also are useful as intermediates for preparing compounds of Formula II in which RW and R 4 are both other than H. In addition, preferred compounds of Formulas I and II are those of subformulas V and VI R2 R 7 BZZD N N o R4 \/E RR V VI wherein R , R2, R4, R7 and R8 are as defined in Formulas I and II and one of B, D and E is N and the others are C. Preferably, D is N. Also, R 4 is preferably pyridyl or phenyl which in each case is substituted or unsubstituted. In accordance with a further aspect of the invention the compounds of formulas I and II are selected from the following compounds: 12 WO 2004/009557 PCT/US2003/022401 7-Methoxy.-2-(2-methyl-( 1,3-dioxolanie-2-yl))-4-[N-(4-pyridylmethyl)] aminobenzofrran, 7-Methoxy-2-(2-methyl-(1 ,3-dioxolane-2-yl))-4-[N-(3-pyridylmethyl)] aminobenzofuran, 7-Methoxy-2-.(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-phenyl-N-(4 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-IIN-(3-cyanophenyl)-N-(3 pyridylmethyl)] aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-phenyl-N-(3 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(3-cyanophenyl)-N-(4 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(4-acetylphenyl)-N-(3 pyridylmethyl)] aminob enzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(4-carboxyphenyl)-N-(3 pyridylmethyl)] aminobeuzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(4-(2H-tetrazol-5-yl)phenyl)-N-(3 pyridylmethyl] aminobenzofiiran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(4-carboxy-3-chlorophenyl)-N-(3 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(3-carboxy-5-fluorophenyl)-N-(3 pyridylinethyl)] aminobenzofuran, 1 -Cyclopentyl-6-[N-(3-(1 , 1 -dimethylethoxycarbonyl)phenyl)-N-(3-pyridylmethyl)]- 1H aminoindazole, 2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(3 -pyridylmethyl))aminobenzofuran, 13 WO 2004/009557 PCT/US2003/022401 2-Acetyl-7-methoxy-4-(N-phenyl-N-(4-pyridylmethyl))aminobenzofuran, 1-Cyclopentyl-6-(N-phenyl-N-(3-pyridylmethyl))aminoindazole, 1-Cyclopentyl-6-(N-(3-carboxyphenyl)-N-(3-pyridylmethyl))aminoindazole, 2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(3-pyridylmethyl))aminobenzofuran, 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-(N-(4-cyanophenyl)-N-(3-pyridylmethyl)) aminobenzofuran, 2-Acetyl-7-methoxy-4-(N-(3-cyanophenyl)-N-(3-pyridylmethyl))aminobenzofuran, 2-Acetyl-7-methoxy-4-(N-phenyl-N-(3-pyridylmethyl))aminobenzofuran, 2-Acetyl-7-methoxy-4-(N-(3-cyanophenyl)-N-(4-pyridylmethyl))aminobenzofuran, 2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(3-pyridylmethyl))aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(4-carboxyphenyl)-N-(3-pyridylmethyl)]aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(4-(2H-tetrazol-5-yl)phenyl)-N-(3-pyridylmethyl]aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(4-carboxy-3-chlorophenyl)-N-(3-pyridylmethyl)] aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(3-carboxy-5-fluorophenyl)-N-(3-pyridyhlethyl)]aminobenzofuran, 6-Amino-1-cyclopentyl-3-ethyl-6-[N-3-(1,1-dimethylethoxycarbonyl)phenyl]-N-(3 pyridylmethyl)amino-1H-indazole, 1-Cyclopentyl-3-ethyl-6-[N-(3-carboxyphenyl)-N-(3-pyridylmethyl)] amino-lH-indazole, 2-Acetyl-7-methoxy-N-(4-phenylsulfonylaminocarbonylphenyl)-N-(3-pyridylmethyl)-4 aminobenzofuran, and pharmaceutically acceptable salts thereof, wherein optically active compounds can be in the form of their separate enantiomers or mixtures thereof, including racemic mixtures. 14 WO 2004/009557 PCT/US2003/022401 The compounds of the present invention are effective in inhibiting, or modulating the activity of PDE4 in animals, e.g., mammals, especially humans. These compounds exhibit neurological activity, especially where such activity affects cognition, including long term memory. These compounds will also be effective in treating diseases where decreased cAMP levels are involved. This includes but is not limited to inflammatory diseases. These compounds may also function as antidepressants, or be useful in treating cognitive and negative symptoms of schizophrenia. Assays for determining PDE inhibiting activity as well as selectivity of PDE 4 inhibiting activity and selectivity of inhibiting PDE 4 isoenzymes are known within the art. See, e.g., U.S. Patent No. 6,136,821, the disclosure of which is incorporated herein by reference. According to a further aspect of the invention there are provided compounds useful as intermediates for the production of the PDE4 inhibitors described herein (e.g., PDE4 inhibitors of Formulas I and II) and/or useful for the synthesis of radio-labeled analogs of the PDE4 inhibitors with in this application. Thus, there are provided intermediate compounds which correspond to compounds of Formulas I and II, wherein R2, R3, R and R are as previously defined for Formulas I and II, but R1 or R 7 is H, tert-butyldimethylsilyl-, or a suitable phenolic or indazolyl protecting group. Suitable protecting groups are described, for example, in Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis, 3 rd Edition, John Wiley & Sons, 1999, pp. 246-293. These intermediates are also useful for the synthesis of radio-labeled compounds, such as where
R
7 is 3
H
3 CO-, 2
H
3 CO-, 1 4
CH
3 - or "CH 3 -, for example by removing the protecting group and reacting the resultant compound in which Ri o R is H with suitable radio-labeled reagents. 15 WO 2004/009557 PCT/US2003/022401 Such radio-labeled compounds are useful for determining compound tissue distribution in animals, in PET imaging studies, and for in vivo, ex vivo, and in vitro binding studies. As previously described, compounds according to formula III, wherein R 4 , R7 and R 8 are as previously described are useful intermediates for the production of compounds according to formula II where in R 3 is other than H. Also, as previously described, compounds according to formula IV, wherein R 3 , R7 and R8 are as previously described are useful intermediates for the production of compounds according to formula II where in R 4 is other than H. Halogen herein refers to F, Cl, Br, and I. Preferred halogens are F and Cl. Alkyl, as a group or substituent per se or as part of a group or substituent (e.g., alkylamino, trialkylsilyloxy, aminoalkyl, hydroxyalkyl), means a straight-chain or branched chain aliphatic hydrocarbon radical having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, especially 1 to 4 carbon atoms. Suitable alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and dodecyl. Other examples of suitable alkyl groups include 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2 dimethylpropyl, 1-ethylpropyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3 dimethylbutyl, 1- or 2-ethylbutyl, ethylmethylpropyl, trimethylpropyl, methylhexyl, dimethylpentyl, ethylpentyl; ethylmethylbutyl, dimethylbutyl, and the like. Substituted alkyl groups are alkyl groups as described above which are substituted in one or more positions by halogens, oxo, hydroxyl, C 1 4 -alkoxy and/or cyano. Halogens are preferred substituents, especially F and Cl. Alkoxy means alkyl-O- groups and alkoxyalkoxy means alkyl-O-alkyl-O- groups in which the alkyl portions are in accordance with the previous discussion. Suitable alkoxy and 16 WO 2004/009557 PCT/US2003/022401 alkoxyalkoxy groups include methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy methoxymethoxy ethoxymethoxy, propoxymethoxy, and methoxyethoxy. Preferred alkoxy groups are methoxy and ethoxy. Similarly, alkoxycarbonyl means alkyl -O-CO- in which the alkyl portion is in accordance with the previous discussion. Examples include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and tert-butoxycarbonyl. Cycloalkyl means a monocyclic, bicyclic or tricyclic nonaromatic saturated hydrocarbon radical having 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, especially 3 to 6 carbon atoms. Suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, 1-decalin, adamant-1-yl, and adamant-2-yl. Other suitable cycloalkyl groups include spiropentyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, spiro[2.4]heptyl, spiro[2.5]octyl, bicyclo[5.1.0]octyl, spiro[2.6]nonyl, bicyclo[2.2.0]hexyl, spiro[3.3]heptyl, bicyclo[4.2.0]octyl, and spiro[3.5]nonyl. Preferred cycloalklyl groups are cyclopropyl, cyclopentyl and cyclohexyl. The cycloalkyl group can be substituted, for example, substituted by halogens and/or alkyl groups. Cycloalkylalkyl refers to cycloalkyl-alkyl radicals in which the cycloalkyl and alkyl portions are in accordance with previous discussions. Suitable examples include cyclopropylmethyl and cyclopentylmethyl. Aryl, as a group or substituent per se or as part of a group or substituent, refers to an aromatic carbocyclic radical containing 6 to 14 carbon atoms, preferably 6 to 12 carbon atoms, especially 6 to 10 carbon atoms. Suitable aryl groups include phenyl, naphthyl and biphenyl. Substituted aryl groups include the above-described aryl groups which are substituted one or more times by, for example, halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, 17 WO 2004/009557 PCT/US2003/022401 ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, and phenoxy. Arylalkyl refers to an aryl-alkyl-radical in which the aryl and alkyl portions are in accordance with the previous descriptions. Suitable examples include benzyl, 1-phenethyl, 2 phenethyl, phenpropyl, phenbutyl, phenpentyl, and napthyhnethyl. Heteroaryl refers to an aromatic heterocyclic group having one or two rings and a total number of 5 to 10 ring atoms wherein at least one of the ring atoms is a heteroatom. Preferably, the heteroaryl group contains 1 to 3, especially 1 or 2, hetero-ring atoms which are selected from N, 0 and S. Suitable heteroaryl groups include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, dithialyl, oxathialyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazolyl, oxathiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, oxazinyl, isoxazinyl, oxathiazinyl, oxadiazinyl, benzofuranyl, isobenzofuranyl, thionaphthenyl, isotbionaphthenyl, indolyl, isoindolyl, indazolyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzisothiazolyl, purinyl, benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, and benzoxazinyl, e.g., 2 thienyl, 3-thienyl, 2-, 3- or 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, and 1-, 3-, 4-, 5-, 6-, 7 or 8-isoquinolinyl. Substituted heteroaryl refers to the heteroaryl groups described above which are substitued in one or more places by, for example, halogen, aryl, alkyl, alkoxy, carboxy, methylene, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, and dialkylamino. Heterocycles include heteroaryl groups as described above as well as non-aromatic cyclic groups containing at least one hetero-ring atom, preferably selected from N, S and 0, for example, tetrahydrofuranyl, piperidinyl, and pyrrolidinyl. 18 WO 2004/009557 PCT/US2003/022401 Heterocycle-alkyl refers to a heterocycle-alkyl-group wherein the heterocyclic and alkyl portions are in accordance with the previous discussions. Suitable examples are pyridylmethyl, thienylmethyl, pyrimidinylmethyl, pyrazinylmethyl, and isoquinolinylmethyl. Partially unsaturated carbocyclic structures are non-aromatic monocyclic or bicyclic structures containing 5 to 14 carbon atoms, preferably 6 to 10 carbon atoms, wherein the ring structure(s) contains at least one C=C bond. Suitable examples are cyclopentenyl, cyclohexenyl, cyclohexadienyl, tetrahydronaphthenyl and indan-2-yl. Alkenyl refers to straight-chain or branched-chain aliphatic radicals containing 2 to 12 carbon atoms in which one or more -CH 2
-CH
2 - structures are each replaced by -CH=CH-. Suitable alkenyl groups are ethenyl, 1-propenyl, 2-methylethenyl, 1-butene, 2-butene, 1 pentenyl, and 2-pentenyl. Alkynyl refers to straight-chain or branched-chain aliphatic radicals containing 2 to 12 carbon atoms in which one or more -CH 2
-CH
2 - structures are each replaced by -C-C-. Suitable alkynyl groups are ethynyl, propynyl, 1-butynyl, and 2-butynyl. Acyl refers to alkanoyl radicals having I to 13 carbon atoms in which the alkyl portion can be substituted by halogen, alkyl, aryl and/or alkoxy, or aroyl radicals having 7 to 15 carbon atoms in which the aryl portion can be substituted by, for example, halogen, alkyl and/or alkoxy. Suitable acyl groups include formyl, acetyl, propionyl, butanoyl and benzoyl. Substituted radicals preferably have 1 to 3 substituents, especially 1 to 2 substituents. In the compounds of Formula I, R 1 can be an alkyl group having preferably 2 to 4 carbon atoms which is optionally substituted by halogen, preferably fluorine or chlorine. R' can also preferably be cycloalkyl, particularly cyclopentyl or cyclohexyl. R2 is preferably H or alkyl having 1 to 4 carbon atoms, especially C 2
H
5 . 19 WO 2004/009557 PCT/US2003/022401
R
3 is preferably hydrogen, alkyl having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, or n-butyl), arylalkyl (e.g., substituted or unsubstitituted benzyl, phenethyl, and phenpropyl), or a heteroarylalkyl group (e.g., substituted or unsubstituted pyridylmethyl, furanylmethyl, thienylmethyl, pyrrolylmethyl, pyrimidinylnethyl, thiazolylmethyl, isoquinolinylmethyl and quinolinylmethyl). Preferred substituents for aryl and heteroaryl portions of R3 are F, Cl, CH 3 ,
C
2
H
5 , OCH 3 , and CN. In particular, R3 is preferably pyridylmethyl.
R
4 is preferably aryl, or heteroaryl, especially phenyl, naphthyl, biphenyl, furanyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, and isoquinolinyl, which in each case is unsubstituted or is substituted one or more times. Preferred substituents are OH, F, Cl, CF 3 , alkyl (such as methyl or ethyl), alkoxy (such as methoxy and ethoxy), CN, vinyl, CH 2 OH, CONHOH, CONH 2 , methylenedioxy, COOH, and combinations thereof. For example, R 4 can be phenyl substituted by halogen, COOH and/or CN. In addition, when R 4 is aryl, especially, phenyl, preferred substituents include R-L-, e.g.,
R
5 -, R 5 -O-, R 5 -CO-, R-1I-CO-, R 5 -S0 2 -NH-, R 5 -S0 2 -NH-alkylene-O-, NH 2 -alkyl-NH-CO-, R-alkylene-NH-CO-, alkyl-CO-NH-alkyl- as well as methyl, ethyl, Cl, F, CN, OCH 3 , CF 3 , amino, nitro, HOCH 2 and COOH. When R 4 is aryl substituted by R 5
-SO
2 -NH- it is preferably a substituted phenyl group and Rs is preferably methyl, ethyl, propyl or phenyl. When R4 is aryl substituted by R 5 -S0 2 -NH-alkylene-O- it is preferably a substituted phenyl. In such cases, R 5 is preferably methyl, ethyl, propyl or phenyl and alkylene is preferably
-CH
2 -, -CH 2
CH
2 - or -CH 2
CH
2
CH
2 -. When R 4 is aryl substituted by R 5 -L- it is preferably substituted phenyl. In such cases, preferred R5 groups include phenyl, tetrazolyl, oxazinyl, piperazinyl, methylpiperazinyl, pyridyl, 20 WO 2004/009557 PCT/US2003/022401 methylpyridyl, pyrrolinyl, methylpyrrolinyl, piperadinyl, or methylpiperadinyl, and L is preferably a single bond, -0-, -CO-, -CH 2 -, -CH 2
CH
2 -, -CH 2
CH
2
CH
2 -, -CH 2 -0-, -CH 2
CH
2 -0-,
-CH
2
CH
2
CH
2 -O-, -CH 2
-NH-CH
2
CH
2 -0-, -CO-NH-, -NH-CO-, or -CONHSO 2 -.
R
7 is preferably alkoxy having 1 to 4 carbon atoms, -which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, e.g., CH 3 or C 2
H
5 . R8 is preferably -CO-C1.4-alkyl, e.g., -COCH3.
R
9 is preferably -CH 3 . X and Y are preferably both 0 or S, especially 0. A is preferably -CH 2
CH
2 -. In addition, preferred PDE4 inhibitors in accordance with the invention are compounds described by subformulas Ia to Ile which correspond to formulas I and II but exhibit the following preferred groups: Ia R 3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and
R
4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted. lb R 1 is cycloalkyl;and R2 is H or C 2
H
5 . Ic R' is cycloalkyl; R is H or C 2
H
5 ; R3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and
R
4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted. Id R 1 is cyclopentyl; 21 WO 2004/009557 PCT/US2003/022401 R2 is H or C2Hs;
R
3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and
R
4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted. Ie R 1 is cyclopentyl; R is H or C2Hs;
R
3 is pyridyl which is substituted or unsubstituted; and
R
4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted. If R' is cyclopentyl; R is H or C2Hs; R2 is pyridyl which is substituted or unsubstituted; and R4 is phenyl which is substituted or unsubstituted. Ila R2 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and R4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted. Ilb R7 is alkoxy having 1 to 4 carbon atoms; R is COCH 3 or Y\ /A
R
9 X
R
9 is -CH 3 ; X and Y are both O or S; and 22 WO 2004/009557 PCT/US2003/022401 A is -CH 2
CH
2 -. Ic R 3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and
R
4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted;
R
7 is alkoxy having 1 to 4 carbon atoms; R8 is COCH 3 or /A R9 X
R
9 is -CH 3 ; X and Y are both O or S; and A is -CH 2
CH
2 -. Id R3 is pyridyl which is substituted or unsubstituted;
R
4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted; Ri is alkoxy having 1 to 4 carbon atoms; R is COCH 3 or A
R
9 X
R
9 is -CH 3 ; X and Y are both O or S; and A is -CH 2
CH
2 -. He R? is pyridyl which is substituted or unsubstituted; 23 WO 2004/009557 PCT/US2003/022401
R
4 is phenyl which is substituted or unsubstituted; R7 is alkoxy having 1 to 4 carbon atoms; R8 is COCH 3 or Y A -X /A
R
9 X
R
9 is -CH 3 ; X and Y are both O or S; and A is -CH 2
CH
2 -. Preferred aspects include pharmaceutical compositions comprising a compound of this invention and a pharmaceutically acceptable carrier and, optionally, another active agent as discussed below; a method of inhibiting a PDE4 enzyme, especially an isoenzyme, e.g., as determined by a conventional assay or one described herein, either in vitro or in vivo (in an animal, e.g., in an animal model, or in a mammal or in a human); a method of treating neurological syndrome, e.g., loss of memory, especially long-term memory, cognitive impairment or decline, memory impairment, etc. a method of treating a disease state modulated by PDE4 activity, in a mammal, e.g., a human, e.g., those mentioned herein. The compounds of the present invention may be prepared conventionally. All starting materials are known or can be conventionally prepared from known starting materials. Some of the processes which can be used are described below. 24 WO 2004/009557 PCT/US2003/022401 '0 -N WO 09809961 N (Ph P(0)N,, N RIN,t-Bu0 H, 100C then6NHCI,THF o 0O N Starting material 6-anino-1-cyclopentyl-3-ethylindazole can be synthesized from the corresponding 6-carboxy-1-cyclopentyl-3-ethylindazole by a Curtius rearrangement. The starting 6-carboxy-1-cyclopentyl-3-ethylindazole can be prepared by methods common in the art (see, e.g., WO 098/09961). Alternatively, starting 6-amino-1-cyclopentyl-3-ethylindazoles can be synthesized by amination of 6-halo-1-cycloalkyl-3-ethylindazole or reduction of 6-nitro-1 cycloalkyl-3-ethylindazole. The indazole scaffold can be prepared by several methods common to the art, such as by reaction of cycloalky1hydrazine with 2,4-difluoropropiophenone.
NO
2 NO02 HNO, Ac 2 0 Ethylene glycol N02 O 0 - cat. p-T sOH, toluene U 0o0 o 0 0 0 TFA DPA patent 0 00 O 0 2 25 WO 2004/009557 PCT/US2003/022401 Starting benzofurans are either commercially available or can be synthesized according literature methods by intramolecular aldol condensation of appropriately substituted beta ketoethers of salicylaldehydes. (see Strategies for Organic Drug Synthesis and Design, Daniel Lednicer, Ed., 1998, John Wiley and Sons, Inc. Chapter 10 pp. 286-289). Nitration of 2-acetyl 7-methoxybenzofuran with nitric acid in acetic anhydride provides 2-acetyl-7-methoxy-4 nitrobenzofuran. (in the above scheme, DPA patent refers to U.S. patent application Serial No. 10/051,309). Protection of the carbonyl group with a suitable base stable protecting group such as a dioxane or dioxolane provides the desired starting 4-nitrobenzofurans. See also WO 99/40085 and WO 99/37640. One of ordinary skill in the art will recognize that some of the compounds of Formulas I and II can exist in different geometrical isomeric forms. In addition, some of the compounds of the present invention possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers, as well as in the form of racemic or nonracemic mixtures thereof, and in the form of diastereomers and diastereomeric mixtures inter alia. All of these compounds, including cis isomers, trans isomers, diastereomic mixtures, racemates, nonracemic mixtures of enantiomers, and substantially pure and pure enantiomers, are within the scope of the present invention. Substantially pure enantiomers contain no more than 5% w/w of the corresponding opposite enantiomer, preferably no more than 2%, most preferably no more than 1%. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate 26 WO 2004/009557 PCT/US2003/022401 acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivation, optimally chosen to maximize the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivitization, are also useful. The optically active compounds of Formulae I and II can likewise be obtained by chiral syntheses utilizing optically active starting materials. In addition, one of ordinary skill in the art will recognize that the compounds can be used in different enriched isotopic forms, e.g., enriched in the content of 2 H, 3 H, 1C and/or 1 4 C. The present invention also relates to useful forms of the compounds as disclosed herein, such as pharmaceutically acceptable salts and prodrugs of all the compounds of the present invention. Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid. Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, mangnesium, ammonium, and choline salts. Those skilled in the art will further recognize that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or 27 WO 2004/009557 PCT/US2003/022401 organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods. The following are further examples of acid salts that can be obtained by reaction with inorganic or organic acids: acetates, adipates, alginates, citrates, aspartates, benzoates, benzenesulfonates, bisulfates, butyrates, camphorates, digluconates, cyclopentanepropionates, dodecylsulfates, ethanesulfonates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, fumarates, hydrobromides, hydroiodides, 2-hydroxy-ethanesulfonates, lactates, maleates, methanesulfonates, nicotinates, 2-naphthalenesulfonates, oxalates, palmoates, pectinates, persulfates, 3-phenylpropionates, pirates, pivalates, propionates, succinates, tartrates, thiocyanates, tosylates, mesylates and undecanoates. Preferably, the salts fonned are pharmaceutically acceptable for administration to mammals. However, pharmaceutically unacceptable salts of the compounds are suitable as intermediates, for example, for isolating the compound as a salt and then converting the salt back to the free base compound by treatment with an alkaline reagent. The free base can then, if desired, be converted to a pharmaceutically acceptable acid addition salt. The compounds of the invention can be administered alone or as an active ingredient of a formulation. Thus, the present invention also includes pharmaceutical compositions of compounds of Formulas I or II containing, for example, one or more pharmaceutically acceptable carriers. Numerous standard references are available that describe procedures for preparing various formulations suitable for administering the compounds according to the invention. Examples of potential formulations and preparations are contained, for example, in the 28 WO 2004/009557 PCT/US2003/022401 Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (current edition); Pharmaceutical Dosage Forms: Tablets (Lieberman, Lachman and Schwartz, editors) current edition, published by Marcel Dekker, Inc., as well as Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current edition). In view of their high degree of PDE4 inhibition, the compounds of the present invention can be administered to anyone requiring or desiring PDE4 inhibition, and/or enhancement of cognition. Administration may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and by ocular administration. Various solid oral dosage forms can be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders. The compounds of the present invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like. Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention. Various liquid oral dosage forms can also be used for administering compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs. Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention. 29 WO 2004/009557 PCT/US2003/022401 The compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible. Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols. Formulations for vaginal administration can be in the form of a pessary, tampon, cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art. For topical administration the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches. Aerosol formulations suitable for administering via inhalation also can be made. For example, for treatment of disorders of the respiratory tract, the compounds according to the invention can be administered by inhalation in the form of a powder (e.g., micronized) or in the form of atomized solutions or suspensions. The aerosol formulation can be placed into a pressurized acceptable propellant. The compounds can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, e.g., other PDE4 inhibitors, calcium channel blockers, chloinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and glanthanamine). In such combinations, each active ingredient can be administered either in accordance with their usual dosage range or a dose below its usual dosage range. 30 WO 2004/009557 PCT/US2003/022401 The present invention further includes methods of treatment that involve inhibition of PDE4 enzymes. Thus, the present invention includes methods of selective inhibition of PDE4 enzymes in animals, e.g., mammals, especially humans, wherein such inhibition has a therapeutic effect, such as where such inhibition may relieve conditions involving neurological syndromes, such as the loss of memory, especially long-term memory. Such methods comprise administering to an animal in need thereof, especially a mammal, most especially a human, an inhibitory amount of a compound, alone or as part of a formulation, as disclosed herein. The condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information. Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline. Dementias are diseases that include memory loss and additional intellectual impairment separate from memory. The present invention includes methods for treating patients suffering from memory impairment in all forns of dementia. Dementias are classified according to their cause and include: neurodegenerative dementias (e.g., Alzheimer's, Parkinson's disease, Huntington's disease, Pick's disease), vascular (e.g., infarcts, hemorrhage, cardiac disorders), mixed vascular and Alzheimer's, bacterial meningitis, Creutzfeld-Jacob Disease, multiple sclerosis, traumatic (e.g., subdural hematoma or traumatic brain injury), infectious (e.g., HIV), genetic (down syndrome), toxic (e.g., heavy metals, alcohol, some medications), metabolic (e.g., vitamin B12 or folate deficiency), CNS hypoxia, Cushing's disease, psychiatric (e.g., depression and schizophrenia), and hydrocephalus. 31 WO 2004/009557 PCT/US2003/022401 The present invention includes methods for dealing with memory loss separate from dementia, including mild cognitive impairment (MCI) and age-related cognitive decline. The present invention includes methods of treatment for memory impairment as a result of disease. In another application, the invention includes methods for dealing with memory loss resulting from the use of general anesthetics, chemotherapy, radiation treatment, post-surgical trauma, and therapeutic intervention. The compounds may be used to treat psychiatric conditions including schizophrenia, bipolar or manic depression, major depression, and drug addiction and morphine dependence. These compounds may enhance wakefulness. PDE4 inhibitors can be used to raise cAMP levels and prevent neurons from undergoing apoptosis. PDE4 inhibitors are also known to be anti inflammatory. The combination of anti-apoptotic and anti-inflammatory properties make these compounds useful to treat neurodegeneration resulting from any disease or injury, including stroke, spinal cord injury, neurogenesis, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), and multiple systems atrophy (MSA). Thus, in accordance with a preferred embodiment, the present invention includes methods of treating patients suffering from memory impairment due to, for example, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia and other neurological conditions including acute neuronal diseases, as well as HIV and cardiovascular diseases, comprising administering an effective amount of a compound according to Formula I or II or pharmaceutically acceptable salts thereof The compounds of the present invention can also be used in a method of treating patients suffering from disease states characterized by decreased NMDA function, such as schizophrenia. 32 WO 2004/009557 PCT/US2003/022401 The compounds can also be used to treat psychosis characterized by elevated levels of PDE 4, for example, various forms of depression, such as manic depression, major depression, and depression associated with psychiatric and neurological disorders. As mentioned, the compounds of the invention also exhibit anti-inflammatory activity. As a result, the inventive compounds are useful in the treatment of a variety of allergic and inflammatory diseases, particularly disease states characterized by decreased cyclic AMP levels and/or elevated phosphodiesterase 4 levels. Thus, in accordance with a further embodiment of the invention, there is provided a method of treating allergic and inflammatory disease states, comprising administering an effective amount of a compound according to Formulas I or II or a pharmaceutically acceptable salt thereof. Such disease states include: asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritis in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and wide-area pyodermias, endogenous and exogenous acne, acne rosacea, Beghet's disease, anaphylactoid purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal diseases, autoimmune diseases and the like. 33 WO 2004/009557 PCT/US2003/022401 PDE4 inhibitors for treating asthma, chronic bronchitis, psoriasis, allergic rhinitis, and other inflammatory diseases, and for inhibiting tumor necrosis factor are known within the art. See, e.g., WO 98/58901, JP-11-18957, JP 10-072415, WO 93/25517, WO 94/14742, US 5,814,651, and US 5,935,9778. These references also describe assays for determining PDE4 inhibition activity, and methods for synthesizing such compounds. The entire disclosures of these documents are hereby incorporated by reference. PDE4 inhibitors may be used to prevent or ameliorate osteoporosis, as an antibiotic, for treatment of cardiovascular disease by mobilizing cholesterol from atherosclerotic lesions, to treat rheumatoid arthritis (RA), for long-term inhibition of mesenchymal-cell proliferation after transplantation, for treatment of urinary obstruction secondary to benign prostatic hyperplasia, for suppression of chemotaxis and reduction of invasion of colon cancer cells, for treatment of B cell chronic lymphocytic leukemia (B-CLL), for inhibition of uterine contractions, to attenuate pulmonary vascular ischemia-reperfusion injury (IRI) , for corneal hydration, for inhibition of IL-2R expression and thereby abolishing HIV-1 DNA nuclear import into memory T cells, for augmentation of glucose-induced insulin secretion, in both the prevention and treatment of colitis, and to inhibit mast cell degranulation. The compounds of the present invention can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, e.g., other PDE4 inhibitors, calcium channel blockers, chloinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and glanthanamine). In such combinations, each active ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range. 34 WO 2004/009557 PCT/US2003/022401 The dosages of the compounds of the present invention depend upon a variety of factors including the particular syndrome to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, pharmacokinetic profile of the compound, and the presence of any deleterious side-effects, among other considerations. The compounds of the invention are typically administered at dosage levels and in a mammal customary for PDE4 inhibitors such as those known compounds mentioned above. For example, the compounds can be administered, in single or multiple doses, by oral administration at a dosage level of, for example, 0.0 1-100 mg/kg/day, preferably 0.1-70 mg/kg/day, especially 0.5-10 mg/kg/day. Unit dosage forms can contain, for example, 0.1-50 mg of active compound. For intravenous administration, the compounds can be administered, in single or multiple dosages, at a dosage level of, for example, 0.001-50 mg/kg/day, preferably 0.001-10 mg/kg/day, especially 0.01-1 mg/kg/day. Unit dosage forms can contain, for example, 0.1-10 mg of active compound. In carrying out the procedures of the present invention it is of course to be understood that reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein. 35 WO 2004/009557 PCT/US2003/022401 The entire disclosures of all applications, patents and publications, cited above and below, and of U.S. Provisional Application No. 60/396,726, filed July 19, 2002, are hereby incorporated by reference. Examples The present invention will now be further described by way of the following non-limiting examples. In applying the disclosure of these examples, it should be kept clearly in mind that other and different embodiments of the methods disclosed according to the present invention will no doubt suggest themselves to those of skill in the relevant art. In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight. EXAMPLE 1 6-Amino-1-cyclopentyl-3-ethyl-1H-indazole To a mixture of 1-cyclopentyl-3-ethyl-1H-indazole-6-carboxylic acid (258 mg) and triethylamine (0.56mL) in t-butanol (iml) was added diphenylphosphoryl azide (0.33 mL). The mixture was stirred at 100 'C for 4h, then partitioned between water (25 mL) and ether (25 mL). The ether layer was collected, dried (MgSO 4 ), and passed through a plug of silica. The silica was washed with an additional 25 mL of ether and the mixture was concentrated in vacuo. The residue was dissolved in THF (5mL) and 6N aq. HCL (lmL) was added and the mixture was stirred for 18h. Ether (25 mL) and water (25 mL) were added and the ether layer was collected, dried (MgSO 4 ), and concentrated in vacuo. The residue was purified by column chromatography on silica gel to yield 0.14 g of 6-amino- 1-cyclopentyl-3-ethyl-1H-indazole (59% yield). 1 H NMR 36 WO 2004/009557 PCT/US2003/022401 (300 MHz) 8 7.45 (d,J=8.4 Hz, 1H), 6.52 (m,2H), 4.74 (p,J=7.8 Hz, 1H), 3.86 (br,2H), 2.95 (q,J=7.7 Hz,2H), 2.3-1.8 (m,6H), 1.8-1.6 (m,2H), 1.37 (t,J=7.7 Hz,3H). EXAMPLE 2 1-Cyclopentyl-3-ethyl-6-[N-(3-pyridymethyl)]amino-1H-indazole To a mixture of 3-pyridinecarboxaldehyde (106 mg, 1.0 mol) in methanol (5.0 mL) was added 6-amino-1-cyclopentyl-3-ethyl-1H-indazole (240 mg, 1.05 mmol) and p-toluenesulfonic acid monohydrate (2.0 mg). The reaction mixture was stirred for 4h. The flask was then cooled to 0 *C and sodium borohydride (0.09g, 2.3 mmol) was added portion-wise over 4h. The reaction mixture was allowed to warm to room temperature over 16h with stirring. TLC indicated the reaction was complete (1:3 hex:EA). The solvent was evaporated and diluted with water (10 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with brine (5 mL), dried over sodium sulfate, and concentrated to yield the desired product. 1 H NMR (300 MHz) 8 8.64 (s, 1H), 8.51 (m,1H), 7.70 (m, 1H), 7.42 (d, J=8.4 Hz, 1H), 7.25 (m, 1H), 6.50 (m,1H), 6.33 (s,lH), 4.68 (p,J=7.8 Hz, 1H), 4.55 (br,1H), 4.40 (s,1H), 2.90 (q,J=7.7 Hz,2H), 2.1-1.8 (m,6H), 1.8-1.6 (m,2H), 1.34 (t,J=7.7 Hz,3H). The following compounds were prepared in a similar manner as described above in Example 2. 1-Cyclopentyl-6-(3-pyridylmethyl)aminoindazole, 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-[N-(3-pyridyhnethyl)] aminobenzofuran, and 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-[N-(4-pyridylmethyl)]aminobenzofuran. 37 WO 2004/009557 PCT/US2003/022401 EXAMPLE 3 6-Amino-1-cyclopentyl-3-ethyl-6-[N-3-(1,1-dimethylethoxycarbonyl)phenyl-N-(3 pyridylmethyl)amino-1H-indazole To a 10 mL oven dried, argon flushed flask was added in the following order 0.06 g (0.61 mmol) of NaOtBu, 36 mg of Pd 2 dba 3 , 2.0 mL of toluene, 0.014 mL of P(tBu) 3 , and a 2.0 mL solution of 140 mg (0.436 mmol) of 6-amino-1-cyclopentyl-3-ethyl-N-(3-pyridylnethyl)-1H indazole in toluene. With stirring, 310 mg (1.5 mmol) of tert-butyl 3-iodobenzoate was added dropwise and the mixture was stirred for 18 hours. The reaction mixture was diluted with EtOAc and washed twice with H20 and extracted with 3 x 15 mL of 3NHCl. The combined acid extracts were washed with 15 mL of EtOAc and then carefully neutralized with 6NNaOH to pH greater than 12. The basic solution was extracted with 2 x 15 mL of EtOAc and the combined organic fractions were subsequently washed with 15 mL of H 2 0 and brine, dried (MgSO 4 ), and concentrated. The residue was purified by chromatography over silica gel (Biotage Flash 40M) eluting with 25% EtOAc in hexanes. 1 HNMR (300 MHz) 8 8.65 (br, 1H), 8.51 (br,1H), 8.26 (d, J=8.4, 1H), 7.75 (m, 1H), 7.7-7.5 (m, 3H), 7.27 (m, 1H), 7.1-7.0 (m, 2H), 6.85 (d, J=8.4,1H),' 5.22 (s,1H), 4.76 (p,J=7.8 Hz, 1H), 2.96 (q,J=7.7 Hz,2H), 2.1-1.8 (m,6H), 1.8-1.6 (m,2H), 1.54 (s,9H), 1.34 (t,J=7.7 Hz,3H). The following compounds were prepared in a similar manner as described above in Example 3. 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-[N-phenyl-N-(4 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-[N-(4-cyanophenyl)-N-(3 pyridylmethyl)]aminobenzofuran, 38 WO 2004/009557 PCT/US2003/022401 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(3-cyanophenyl)-N- (3 pyridylmethyl)] aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-phenyl-N-(3 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-(1 ,3-dioxolane-2-yl))-4-[N-(3-cyanophenyl)-N-(4 pyridyhnethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(4-acetylphenyl)-N-(3 pyridylmetliyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolanie-2-yl))-4-[N-(4-carboxyphenyl)-N-(3 pyridylmethyl)] aminobeuzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(4-(2H-tetrazol-5-yl)phenyl)-N-(3 pyridylmethyl]amninobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4- [N-(4-carboxy-3-chlorophenyl)-N-(3 pyridylmethyl)]amninobenzofuran, 7-Methoxy-2-(2-methyl-(1 ,3-dioxolane-2-yl))-4-[N-(3-carboxy-5-fluorophenyl)-N-(3 pyridylmethyl)] aminobenzofuran, 1 -Cyclopentyl-6-[N-phenyl-N-(3 -pyridylmethyl)]aminoindazole, and 1 -Cyclopentyl-6-[N-(3-(1 , 1-dimethylethoxycarbonyl)phenyl)-N-(3 -pyridylmethyl)] - H aminoindazole. 39 WO 2004/009557 PCT/US2003/022401 EXAMPLE 4 6 -Amino-1-Cyclopentyl-3-ethyl-6-[N-(3-carboxyphenyl)-N-(3-pyridylmethyl)]amino-1H indazole A solution consisting of 170 mg (0.344 mmol) of 6-amino-1-cyclopentyl-3-ethyl-N-[3 (1,1-dimethylethoxycarbonyl)phenyl]-N-(3-pyridylmethyl)-1H-indazole, 3.35 mL of dichloromethane and 0.84 mL of trifluoroacetic acid was stirred at room temperature for 5 hours. The solution was washed with 5.0 mL of H 2 0. Then 5.0 mL of H 2 0 was added and the pH adjusted to 6 by the addition of 10% aqueous NaOH. The combined aqueous layers were extracted with 2 x 5 mL of dichloromethane. The combined dichloromethane extracts were evaporated and the remaining material was purified by flash chromatography over SiO 2 using 10% MeOH in CH 2 C1 2 as eluant. 1H NMR (300 MHz) 3 8.90 (br, 1H), 8.70 (br,lH), 8.25 (d, J=8.4, 1H), 7.7-7.5 (m, 4H), 7.20 (m, 1H), 7.1-7.0 (m, 2H), 6.86 (d, J=8.4,1H), 5.20 (s,1H), 4.76 (p,J=7.8 Hz, 1H), 2.96 (q,J=7.7 Hz,2H), 2.05 (m,4H), 1.88 (m,2H), 1.65 (m,2H), 1.36 (t,J=7.7 Hz,3H). The following compound was prepared in a similar manner as described above in Example 4. 1-Cyclopentyl-6-[N-(3-carboxyphenyl)-N-(3-pyridylmethyl)]aminoindazole. EXAMPLE 5 2-Acetyl-7-methoxy-4-nitrobenzofuran To a solution of 2-acetyl-7-methoxybenzofuran (4.0 g) in acetic anhydride (50 mL) at 0 0 C was added 70% nitric acid (1.5 mL) drop-wise. The mixture was warmed to room temperature and stirred for 3h then poured into ice-cold saturated sodium carbonate (200 mL). Solid sodium carbonate was added carefully with stirring until basic (pH=8). The mixture was 40 WO 2004/009557 PCT/US2003/022401 filtered and the solid collected by vacuum filtration. The solid was boiled in 100 mL (methanol) for lh, then cooled to 0 0 C and filtered to give 2-acetyl-7-methoxy-4-nitrobenzpfuran (2.1g). 1 H NMR (300 MHz) 5 8.29 (d,J=8.9 Hz, 1H), 8.14 (s,1H), 7.00 (d,J=8.9 Hz, 1H), 4.14 (s,3H), 2.68 (s, 3H). EXAMPLE 6 7-Methoxy-2-(2-methyl-(1,3-dioxolan-2-yl))-4-nitrobenzofuran A mixture of 2-acetyl-7-methoxy-4-nitrobenzofuran (2.1 g), ethylene glycol (2 mL), and p-toluensulfonic acid (25 mg) in toluene (50 mL) was warmed to reflux with an attached Dean Stark apparatus for 18h. The mixture partitioned between sat. aq. NaHCO 3 (50 mL) and ether (50 mL). The ether layer was collected, washed with water (25 mL) and brine (25 mL), dried (MgSO 4 ) and concentrated to give pure 7-methozy-2-(2-methyl-(1,3-dioxolan-2-yl))-4 nitrobenzofuran (2.1g). 1 H NMR (300 MHz) 8 8.22 (d,J=9.0 Hz, 1H), 7.44 (s,lH), 6.84 (d,J=9.0 Hz, 1H), 4.11 (s,3H), 4.11 (m,4H), 1.86 (s,3H). EXAMPLE 7 4-Amino-7-methoxy-2-(2-methyl-(1,3-dioxolan-2-yl))-benzofuran To a suspension of 10% Pd on activated carbon (200 mg) in ethanol (100 mL), under N 2 protection, was added 7-methoxy-2-(2-methyl-(1,3-dioxolan-2-yl))-4-nitrobenzofuran (6.50 g, 23 mmol). The reaction mixture was degassed under vacuum three times. The reaction mixture was stirred vigorously while hydrogen gas was allowed to flow over the reaction mixture. After 4h the reaction was complete by TLC (5:1 hex:EA). The reaction mixture was filtered through a pad of celite and the celite was rinsed with additional ethanol. The solvent was removed in vacuo to obtain 5.1 g (88% yield) of the title compound as a yellow oil. 41 WO 2004/009557 PCT/US2003/022401 EXAMPLE 8 2 -Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(3-pyridylmethyl)aminobenzofuran 7-Methoxy-2-(2-methyl-1,3-dioxolan-2-yl)-4-(N-3-carboxyphenyl)-N-(3 pyridylmethyl)aminobenzofuran, t-butyl ester (120 mg) was taken up in CH 2 Cl 2 (10 mL) and trifluoroacetic acid (2 mL) was added and the mixture was stirred for 4h. The mixture was concentrated in vacuo and the residue was purified by column chromatography eluting with a linear gradient from 0%-10% MeOH in EtOAc over 15 min to yield 65 mg of 2-acetyl-7 methoxy-4-(N-(3-carboxyphenyl)-N-)3-pyridylmethyl)aminobenzofuran. H NMR (300 MHz) o 11.60 (br,1H,) 8.71 (br,1H), 8.56 (br,1H), 7.80 (d,J=7.5 Hz, 1H), 7.60-7>50 (m,2H), 7.35 (m,1H), 7.20 (t,J=7.9 Hz, 1H), 7.10-7.00 (m,2H), 6.95-6.80 (m,2H), 5.09 (s,2H), 4.01 (s,3H), 2.54 (s,3H). The following compounds were prepared in a similar manner as described above in Example 8. 2-Acetyl-7-methoxy-4-[N-phenyl-N-(4-pyridylmethyl)]aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(4-cyanophenyl)-N-(3-pyridylmethyl)]aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(3-cyanophenyl)-N-(3-pyridylmethyl)]aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-phenyl-N-(3-pyridyhnethyl)]aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(3-cyanophenyl)-N-(4-pyridylmethyl)]aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(4-acetylphenyl)-N-(3-pyridylmethyl)] aminobenzofuran, 2 -Acetyl-7-methoxy-4-[N-(4-carboxyphenyl)-N-(3-pyridylmethyl)]aminobenzofuran, 2 -Acetyl-7-methoxy-4-[N-(4-(2H-tetrazol-5-yl)phenyl)-N-(3-pyridylmethyl]aminobenzofuran, 42 WO 2004/009557 PCT/US2003/022401 2-Acetyl-7-methoxy-4-[N-(4-carboxy-3-chlorophenyl)-N-(3-pyridylmethyl)]aminobenzofuran, and 2-Acetyl-7-methoxy-4-[N-(3-carboxy-5-fluorophenyl)-N-(3-pyridylmethyl)]aminobenzofuran. EXAMPLE 9 2-Acetyl-7-methoxy-N-(4-phenylsulfonylaminocarbonylphenyl)-N-(3-pyridylmethyl)-4 aminobenzofuran To a solution of 2-acetyl-7-methoxy-N-(4-carboxyphenyl)-N-(3-pyridylmethyl)-4 aminobenzofuran (416 mg, 1.0 mmol), benzenesulfonamide (200 mg, 1.2 mmol), and DMAP (150 mg, 1.2 mmol) in dichloromethane (5 mL) at room temperature was added EDCI (230 mg, 1.2 mmol) in one portion and the mixture was stirred at room temperature for 16h. The mixture was partitioned between water (25 mL) and EtOAc (25 mL) and the pH was adjusted to 5-6 with 1.ON HCl. The EtOAc was separated, washed with brine (25 mL), dried (MgSO 4 ) and concentrated in vacuo. The residue was purified by column chromatography eluting with a linear gradient from 5% to 10% MeOH in EtOAc to give 2-Acetyl-7-methoxy-N-(4 phenylsulfonylaminocarbonylphenyl)-N-(3-pyridylmethyl)-4-aminobenzofuran (415 mg). 1H NMR (300 MHz) 8 8.53 (br,1H), 8.46 (br,1H), 8.06 (d,J=7.3 Hz,2H), 7.8-7.3 (m,6H), 7.21 (m,1H), 7.1-7.0 (m,2H), 6.91 (d,J=8.5 Hz,1H), 6.56 (d,J=7.3 Hz,2H), 4.99 (s,2H), 4.02 (s,3H), 2.54 (s,3H). EXAMPLE 10 In Vitro Measurement of Type 4 Phosphodiesterase Inhibition Activity Human PDE4 was obtained from baculovirus-infected Sf9 cells that expressed the recombinant enzyme. The cDNA encoding hPDE-4D6 was subcloned into a baculovirus vector. Insect cells (Sf9) were infected with the baculovirus and cells were cultured until protein was 43 WO 2004/009557 PCT/US2003/022401 expressed. The baculovirus-infected cells were lysed and the lysate was used as source of hPDE 4D6 enzyme. The enzyme was partially purified using a DEAE ion exchange chromatography. This procedure can be repeated using cDNA encoding other PDE-4 enzymes. Assay: Type 4 phosphodiesterases convert cyclic adenosine monophosphate (cAMP) to 5' adenosine monophosphate (5'-AMP). Nucleotidase converts 5'-AMP to adenosine. Therefore the combined activity of PDE4 and nucleotidase converts cAMP to adenosine. Adenosine is readily separated from cAMP by neutral alumina columns. Phosphodiesterase inhibitors block the conversion of cAMP to adenosine in this assay; consequently, PDE4 inhibitors cause a decrease in adenosine. Cell lysates (40 ul) expressing hPDE-4D6 were combined with 50 ul of assay mix and 10 ul of inhibitors and incubated for 12 min at room temperature. Final concentrations of assay components were: 0. 4 ug enzyme, 10mM Tris-HCl (pH 7.5), 10mM MgCl 2 , 3 uM cAMP, 0.002 U 5'-nucleotidase, and 3 x 104 cpm of [3H]cAMP. The reaction was stopped by adding 100 pl of boiling 5miN HC1. An aliquot of 75 1l of reaction mixture was transferred from each well to alumina columns (Multiplate; Millipore). Labeled adenosine was eluted into an OptiPlate by spinning at 2000 rpm for 2 min; 150 pl per well of scintillation fluid was added to the OptiPlate. The plate was sealed, shaken for about 30 min, and cpm of [ 3 H]adenosine was determined using a Wallac Triflux*. All test compounds are dissolved in 100% DMSO and diluted into the assay such that the final concentration of DMSO is 0.1%. DMSO does not affect enzyme activity at this concentration. 44 WO 2004/009557 PCT/US2003/022401 A decrease in adenosine concentration is indicative of inhibition of PDE activity. pIC 5 o values were determined by screening 6 to 12 concentrations of compound ranging from 0.1 nM to 10,000 nM and then plotting drug concentration versus 3 H-adenosine concentration. Nonlinear regression software (Assay Explorer*) was used to estimate pIC 5 o values. EXAMPLE 11 (Method A) Passive Avoidance in Rats, an in vivo Test for Learning and Memory The test was performed as previously described (Zhang, H.-T., Crissman, A.M., Dorairaj, N.R., Chandler, L.J., and O'Donnell, J.M., Neuropsychopharmacology, 2000, 23, 198-204.). The apparatus (Model E10-16SC, Coulbourn Instruments, Allentown, PA) consisted of a two compartment chamber with an illuminated compartment connected to a darkened compartment by a guillotine door. The floor of the darkened compartment consisted of stainless steel rods through which an electric foot-shock could be delivered from a constant current source. All experimental groups were first habituated to the apparatus the day before the start of the experiment. During the training, the rat (Male Spraque-Dawley (Harlan) weighing 250 to 350 g) was placed in the illuminated compartment facing away from the closed guillotine door for 1 minute before the door was raised. The latency for entering the darkened compartment was recorded. After the rat entered the darkened compartment, the door was closed and a 0.5 mA electric shock was administered for 3 seconds. Twenty-four hours later, the rat was administered 0.1 mg/kg MK-801 or saline, 30 minutes prior to the injection of saline or test compound (dosed from 0.1 to 2.5 mg/kg, i.p.), which was 30 minutes before the retention test started. The rat was again placed in the illuminated compartment with the guillotine door open. The latency for entering the darkened compartment was recorded for up to 180 seconds, at which time the trial was terminated. 45 WO 2004/009557 PCT/US2003/022401 All data were analyzed by analyses of variance (ANOVA); individual comparisons were made using Kewman-Keuls tests. NaYve rats required less than 30 seconds, on average, to cross from the illuminated compartment to the darkened compartment. However, 24 hours after the electric shock exposure, most rats pretreated with vehicle did not re-enter the darkened compartment; the average latency was increased up to 175 seconds (p < 0.001). Pretreatment with MK-801 (0.1 mg/kg) markedly reduced this latency when compared to the vehicle (p<0.001). This amnesic effect of MK-801 is reversed in a statistically significant manner by actual test compounds in a dose-dependent fashion. EXAMPLE 11 (Method B) Radial arm maze task in Rats, an in vivo Test for Learning and Memory The test was perfonned as previously described (Zhang, H.-T., Crissman, A.M., Dorairaj, N.R., Chandler, L.J., and O'Donnell, J.M., Neuropsychopharmacology, 2000, 23, 198-204.). Five days after initial housing, rats (male Spraque-Dawley (Harlan) weighing 250 to 350 g) were placed in the eight-arm radial maze (each arm was 60x10x12 cm high; the maze was elevated 70 cm above the floor) for acclimation for two days. Rats were then placed individually in the center of the maze for 5 minutes with food pellets placed close to the food wells, and then, the next day, in the wells at the end of the arms; 2 sessions a day were conducted. Next, four randomly selected arms were then baited with one pellet of food each. The rat was restricted to the center platform (26 cm in diameter) for 15 seconds and then allowed to move freely throughout the maze until it collected all pellets of food or 10 minutes passed, whichever came first. Four parameters were recorded: 1) working memory errors, i.e., entries into baited arms that had already been visited during the same trial; 2) reference memory errors, i.e., entries into unbaited arms; 3) total arm entries; and 4) the test duration (seconds), i.e., the time spent in the 46 P\WPDOCS\DIffSPECI\l2513301 Mc y IStSPA doc-I8/09/2009 collection of all the pellets in the maze. If the working memory error was zero and the average reference memory error was less than one in five successive trials, the rats began the drug tests. MK-801 or saline was injected 15 minutes prior to vehicle or test agent, which was given 45 minutes before the test. Experiments were performed in a lighted room, which contained several extra-maze visual cues. All data were analyzed by analyses of variance (ANOVA); individual comparisons were made using Kewman-Keuls tests. Compared to control, MK-801 (0.1 mg/kg, i.p.) increased the frequencies of both working and reference memory errors (p<O. 01). This amnesic effect of MK- 801 on working memory is reversed in a statistically significant manner by the administration of actual test compounds in a dose-dependent fashion. The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples. While the invention has been illustrated with respect to the production and of particular compounds, it is apparent that variations and modifications of the invention can be made without departing from the spirit or scope of the invention. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as, an acknowledgement or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. 47

Claims (57)

  1. 2. A compound of claim 1, which is of formula III or IV: R7 R o NH O NR - R4 - H R 8 R 8 Ill IV wherein R 3 is H, alkyl having I to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, CI- 4 -alkoxy, or combinations thereof, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion which is branched or unbranched has I to 5 carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, CI- 4 -alkoxy, cyano or combinations thereof, arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, or heteroarylalkyl group, wherein the heteroaryl portion may be partially or fully saturated and has 5 to 10 ring atoms in which at least I ring atom is a N, 0 or S atom, the alkyl portion, which is branched or unbranched, has 1 to 5 carbon atoms, the heteroarylalkyl group is unsubstituted or substituted one or more times in the heteroaryl portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof; 52 P:\WPDOCS\DHISPECl12513301 Mcmory IsISPAdec-18/09/2009 R 4 is H, aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 , amino, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, 2( heterocycle)tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 -L-, or combinations thereof, or heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, RS-L-, or combinations thereof; RT 7 is alkoxy or alkylthio, in each case having I to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen; R is -CO-C 1 4 -alkyl which is branched or unbranched and where the alkyl is unsubstituted or substituted one or more times by halogen, or is Y A R 9 X or Y-R10 R 9 X-R or a pharmaceutically acceptable salt thereof; wherein an optically active compound can be in the form of one of its separate enantiomers or mixtures thereof, including racemic mixtures. 53 P:\WPDOCS\DISPECl\12513301 Mcmry IstSPA doc-1/09/2009
  2. 3. A compound of claim 1, which is of the subformula VI: R R O N*' D R 8 wherein R 4 is H, aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 , amino, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, 2( heterocycle)tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 -L-, or combinations thereof, or heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 -L-, or combinations thereof; R' 7 is alkoxy or alkylthio, in each case having I to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen; Ra 8 is -CO-CI 4 -alkyl which is branched or unbranched and where the alkyl is unsubstituted or substituted one or more times by halogen, or is 54 P:\WPDOCS\DHrlSPECI\12513301 Mcmory IstSPA doc- 1809/2009 Y A R 9 X or Y-R 1 R 9 X-R and one of B, D and E is N and the other two are C; or a pharmaceutically acceptable salt thereof, wherein an optically active compound can be in the form of one of its separate enantiomers or mixtures thereof, including racemic mixtures.
  3. 4. A compound of claim 3, wherein D is N and B and E are C.
  4. 5. A compound of claim 3, wherein R 4 is pyridyl or phenyl which are unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 , amino, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, 2( heterocycle)tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy, R 5 -L-, or combinations thereof.
  5. 6. A compound of claim 1, which is:
  6. 7-Methoxy-2-(2-methyl-( 1 ,3-dioxolane-2-yl))-4-[N-(4-pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-[N-(3-pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-[N-phenyl-N-(4 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-[N-(3-cyanophenyl)-N-(3 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-[N-phenyl-N-(3 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-(1,3-dioxolane-2-yl))-4-[N-(3-cyanophenyl)-N-(4 55 P \WPDOCSDfHTISPECI\I 2313301 M.-cy IsSPAd. IS/092W9 pyridylmethyl)] aminobenzofuran, 7-Methoxy-2-(2-methyl-(1I,3-dioxolane-2-yl))-4-[N-(4-acetylphenyl)-N-(3 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(4-carboxyphenyl)-N-(3 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(4-(2H-tetrazol-5-yl)phenyl)-N-(3 pyridylmethyll aminobenzofuran, 7-Methoxy-2-(2-methyl-(1I,3-dioxolane-2-yl))-4-[N-(4-carboxy-3-chlorophenyl)-N-(3 pyridylmethyl)]aminobenzofuran, 7-Methoxy-2-(2-methyl-( 1,3-dioxolane-2-yl))-4-[N-(3-carboxy-5-fluorophenyl)-N-(3 pyridylmethyl)]aminobenzofuran, 2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(3-pyridylmethyl))aminobenzofuran, 2-Acetyl-7-methoxy-4-(N-phenyl-N-(4-pyridylmethyl))aminobenzofuran, 2 -Acetyl-7 -methox y-4-(N-(3 -carbox yphenyl)-N-(3 -pyri dyl methyl))am inobenzofu ran, 7-Methoxy-2-(2-methyl-(1I,3-dioxolane-2-yl))-4-(N-(4-cyanophenyl)-N-(3 pyridylmethyl))-aminobenzofuran, 2-Acetyl-7-methoxy-4-(N-(3-cyanophenyl)-N-(3-pyridylmethyl))aminobenzofuran, 2-Acetyl-7-m-ethoxy-4-(N-phenyl-N-(3-pyridylmethyl))aminobenzofuran, 2-Acetyl-7-methoxy-4-(N-(3-cyanophenyl)-N-(4-pyridylmethyl))aminobenzofuran, 2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(3-pyridylmethyl))aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(4-carboxyphenyl)-N-(3-pyridylmethyl)]aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(4-(2H-tetrazol-5-yl)phenyl)-N-(3 pyridylmethyl]aminobenzofuran, 2-Acetyl-7-methoxy-4-[N-(4-carboxy-3-chlorophenyl)-N-(3 pyridylmethyl)]aminobenzofuiran, 2-Acetyl-7-methoxy-4-[N-(3-carboxy-5-fluorophenyl)-N-(3 pyridylmethyl)]aminobenzofuran, 2-Acetyl-7-methoxy-N-(4-phenylsul fonylarniinocarbonylphenyl)-N-(3 -pyridylmethyl] -4 aminobenzofuran, or a pharmaceutically acceptable salt thereof, 56 P.\WPDOCS\DHITSPECI\l2513301 Maory ISPA.doc- I 8/0912009 wherein optically active compounds can be in the form of their separate enantiomers or mixtures thereof, including racemic mixtures. 7. A compound of claim 1, wherein: each aryl group is, independently, a phenyl, naphthyl or biphenyl group optionally substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof; each heteroaryl group is, independently, a furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, dithianyl, oxathianyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazolyl, oxathiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, oxazinyl, isoxazinyl, oxathiazinyl, oxadiazinyl, benzofuranyl, isobenzofuranyl, thionaphthenyl, isothionaphthenyl, indolyl, isoindolyl, indazolyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzisothiazolyl, purinyl, benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, or benzoxazinyl group optionally substituted in one or more places by halogen, aryl, alkyl, alkoxy, carboxy, methylene, cyano, trifluoromethyl, nitro, amino, alkylamino, dialkylamino, or combinations thereof; and each heterocycle group is, independently, a heteroaryl group as stated above or a tetrahydrofuranyl, piperidinyl, or pyrrolidinyl group optionally substituted as stated above.
  7. 8. A compound of claim 1, wherein: R 3 is hydrogen; alkyl having 1 to 4 carbon atoms; substituted or unsubstituted benzyl, phenethyl, or phenpropyl; or substituted or unsubstituted pyridylmethyl, furanylmethyl, thienylmethyl, pyrrolylmethyl, pyrimidinylmethyl, thiazolylmethyl, isoquinolinylmethyl or quinolinylmethyl; and R 4 is phenyl, naphthyl, biphenyl, furanyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, or isoquinolinyl, which in each case is unsubstituted or is substituted one or more times by OH, F, Cl, CF 3 , alkyl, alkoxy, CN, vinyl, CH 2 OH, CONHOH, CONH 2 , methylenedioxy or COOH, or R 4 is phenyl, naphthyl, or biphenyl which in each case is optionally substituted by 57 P:\WPDOCS\DIMSPECI\12513301 Mcmory IstSPA doc.18/09/2009 R 5 -, R 5 -O-, R 5 -CO-, R 5 -NH-CO-, R 5 -SO 2 -NH-, R 5 -S0 2 -NH-alkylene-O-, NH 2 -alkyl-NH CO-, R 5 -alkylene-NH-CO-, alkyl-CO-NH-alkyl-, methyl, ethyl, Cl, F, CN, OCH 3 , CF 3 , amino, nitro, HOCH 2 , COOH, or combinations thereof; R 7 is alkoxy having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen; and R 8 is -CO-C . 4 -alkyl.
  8. 9. A compound of claim 1, wherein: R 3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted.
  9. 10. A compound of claim 1, wherein: R 3 is pyridyl which is substituted or unsubstituted; and R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted. I1. A compound of claim 1, wherein: R 3 is pyridyl which is substituted or unsubstituted; and R 4 is phenyl which is substituted or unsubstituted.
  10. 12. A compound of claim 1, wherein: R 7 is alkoxy having I to 4 carbon atoms; R is COCH 3 or Y A R 9 X R 9 is -CH 3 ; X and Y are both 0 or S; and A is -CH 2 CH 2 -
  11. 13. A compound of claim 1, wherein: R 3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted; 58 PAWPDOCS\DHTMSPECl\l2513301 Mnory WSPAdo-18/09/2009 R 7 is alkoxy having I to 4 carbon atoms; R is COCH 3 or A R 9 X R 9 is -CH 3 ; X and Y are both 0 or S; and A is -CH 2 CH 2 -.
  12. 14. A compound of claim 1, wherein: R 3 is pyridyl which is substituted or unsubstituted; R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted; R 7 is alkoxy having I to 4 carbon atoms; R 8 is COCH 3 or Y A R 9 X R 9 is -CH 3 ; X and Y are both 0 or S; and A is -CH 2 CH 2 -.
  13. 15. A compound of claim 1, wherein: R 3 is pyridyl which is substituted or unsubstituted; R 4 is phenyl which is substituted or unsubstituted; R 7 is alkoxy having 1 to 4 carbon atoms; R 8 is COCH 3 or Y A R 9 X R 9 is -CH 3 ; 59 P:\WPDOCS\DH1\SPECI\12513301 Mnoy IsSPA do- 1/09/209 X and Y are both 0 or S; and A is -CH 2 CH 2 -.
  14. 16. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
  15. 17. A composition of claim 16, wherein the compound of claim I is provided in a unit dosage of 0.1 - 50 mg.
  16. 18. A method for effecting PDE4 enzyme inhibition, enhancing cognition and/or treating psychosis in a patient comprising administering to said patient an effective amount of a compound according to any one of claims 1-15.
  17. 19. A method according to claim 18, wherein said patient is a human.
  18. 20. A method of claim 18, wherein the patient is suffering from cognition impairment or decline.
  19. 21. A method according to claim 18, wherein said patient is suffering from memory impairment.
  20. 22. A method according to claim 21, wherein said patient is suffering from memory impairment due to Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, HIV, cardiovascular disease, head trauma or age-related cognitive decline.
  21. 23. A method according to claim 21, wherein said patient is suffering from memory impairment due to dementia.
  22. 24. A method according to claim 18, wherein said patient is suffering from a psychosis.
  23. 25. A method according to claim 24, wherein said patient is suffering from 60 P:\WPDOCS\DTISPECI~I2513301 Manory IsiSPAdoc-I 8/0912009 schizophrenia, bipolar or manic depression, or major depression.
  24. 26. A method for treating a patient having a disease involving decreased cAMP levels comprising administering to said patient an effective amount of a compound according to any one of claims 1-15.
  25. 27. A method of claim 18 wherein the patient is treated to effect PDE4 enzyme inhibition.
  26. 28. A method of treating a patient suffering from an allergic or inflammatory disease comprising administering to said patient an effective amount of a compound according to any one of claims 1-15.
  27. 29. A method of treating a patient suffering from neurodegeneration resulting from a disease or injury comprising administering to said patient an effective amount of a compound according to any one of claims 1-15.
  28. 30. A method according to claim 29, wherein the disease or injury is stroke, spinal cord injury, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), or multiple systems atrophy (MSA).
  29. 31. A method according to claim 21, wherein said patient is suffering from memory impairment due to Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia, an acute neuronal disease, HIV or a cardiovascular disease.
  30. 32. A method according to any one of claims 18-31, wherein the compound is administered in combination with one or more pharmaceutical agents used in the treatment of cognitive impairment and/or in the treatment psychosis.
  31. 33. A method according to claim 32, wherein said one or more pharmaceutical agents 61 PAWPDOCS\DiMSPECI\12513301 Manory IstSPAdoc.18/09/2009 are selected from PDE-4 inhibitors, calcium channel blockers, cholinergic drugs, adenosine receptor modulators, ampakines, NMDA-R modulators mGluR modulators, and cholinesterase inhibitors.
  32. 34. A compound according to claim 1, wherein R 3 is methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3 or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, ethylmethylpropyl, trimethylpropyl, methylhexyl, dimethylpentyl, ethylpentyl, ethylmethylbutyl, dimethylbutyl, or an alkyl having I to 8 carbon atoms, which is branched or unbranched and which is substituted one or more times with halogen.
  33. 35. A compound according to claim 1, wherein R 4 is phenyl, naphthyl or biphenyl, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof, and acyl is an alkanoyl radical having I to 13 carbon atoms in which the alkyl portion is unsubstituted or substituted by halogen, alkyl, aryl, alkoxy, or combinations thereof, or acyl is an aroyl radical having 7 to 15 carbon atoms in which the aryl portion is unsubstituted or substituted by halogen, alkyl, alkoxy or combinations thereof.
  34. 36. A compound according to claim 1, wherein R 3 is benzyl, I -phenethyl, 2-phenethyl, phenpropyl, phenbutyl, phenpentyl, or napthylmethyl.
  35. 37. A compound according to claim 1, wherein R 4 is furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, dithianyl, oxathianyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazolyl, oxathiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, oxazinyl, isoxazinyl, oxathiazinyl, oxadiazinyl, benzofuranyl, isobenzofuranyl, thionaphthenyl, isothionaphthenyl, indolyl, isoindolyl, indazolyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzisothiazolyl, purinyl, benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, 62 P:\WPDOCS\DIHTSPECI\12513301 NIory IstSPA doc-I /09/2009 or benzoxazinyl, which in each case is unsubstituted or substituted in one or more places by halogen, aryl, alkyl, alkoxy, carboxy, methylene, cyano, trifluoromethyl, nitro, amino, alkylamino, dialkylamino, or combinations thereof.
  36. 38. A compound according to claim 1, wherein R 4 is 2-thienyl, 3-thienyl, 2-, 3- or 4 pyridyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, or 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl, which in each case is unsubstituted or substituted in one or more places by halogen, aryl, alkyl, alkoxy, carboxy, methylene, cyano, trifluoromethyl, nitro, amino, alkylamino, dialkylamino, or combinations thereof.
  37. 39. A compound according to claim 1, wherein R 3 is hydrogen, methyl, ethyl, n-propyl, n-butyl, benzyl, benzyl substituted by F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof, phenethyl, phenethyl substituted by F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof, phenpropyl, phenpropyl substituted by F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof, pyridylmethyl, pyridylmethyl substituted by are F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof, furanylmethyl, furanylmethyl substituted by are F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof, thienylmethyl, thienylmethyl substituted by are F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof, pyrrolylmethyl, pyrrolylmethyl substituted by are F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof, pyrimidinylmethyl, pyrimidinylmethyl substituted by are F, Cl, CH 3 , C 2 R 5 , OCH 3 , CN, or combinations thereof, thiazolylmethyl, thiazolylmethyl substituted by are F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof, isoquinolinylmethyl, isoquinolinylmethyl substituted by are F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof, quinolinylmethyl, or quinolinylmethyl substituted by are F, Cl, CH 3 , C 2 H 5 , OCH 3 , CN, or combinations thereof.
  38. 40. A compound according to claim 1, wherein R 4 is phenyl, naphthyl, biphenyl, furanyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, or isoquinolinyl, which in each case is unsubstituted or is substituted one or more times by OH, F, Cl, CF 3 , methyl, ethyl, methoxy, ethoxy, CN, vinyl, CH 2 OH, CONHOH, CONH 2 , methylenedioxy, COOH, or combinations thereof 63 ?\WPDOCS\D T\SPECi\l2513301 Mmory I siSPAdc-18/09/2009
  39. 41. A compound according to claim 1, wherein R 4 is phenyl which is unsubstituted or is substituted one or more times by OH, F, Cl, CF 3 , methyl, ethyl, methoxy, ethoxy, CN, vinyl, CH 2 OH, CONHOH, CONH 2 , methylenedioxy, COOH, or combinations thereof.
  40. 42. A compound according to claim 1, wherein R 3 is pyridylmethyl.
  41. 43. A compound according to claim 41, wherein R 3 is pyridylmethyl.
  42. 44. A method of treating a patient suffering from drug addiction or morphine dependence comprising administering to said patient an effective amount of a compound according to any one of claims 1-15.
  43. 45. A method according to claim 28, wherein said patient is suffering from inflammation due to asthma, chronic bronchitis, chronic obstructive pulmonary disease, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium, reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, toxic contact eczema, allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritis in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular pyodermias, wide-area pyodermias, endogenous acne, exogenous acne, acne rosacea, Behcet's disease, anaphylactoid purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal disease, or autoimmune disease.
  44. 46. A compound according to claim 1, wherein R 3 is H, alkyl having I to 8 carbon atoms, which is branched or unbranched, and which is substituted one or more times with halogen, cyano, C- 4 -alkoxy, or combinations 64 P WPDOCS\DIHTSPEC\12513301 Mcmory I sSPA doc- 18/09/2009 thereof, a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion which is branched or unbranched has I to 5 carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, Cj 4 -alkoxy, cyano or combinations thereof, arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has I to 5 carbon atoms, arylalkyl radical is unsubstituted or substituted, in the aryl portion, one or more times by halogen, trifluoromethyl, CF 3 0, nitro, amino, alkyl, alkoxy, alkylamino, dialkylamino and/or substituted in the alkyl portion by halogen, cyano, or methyl, or heterocycle-alkyl group, wherein the heterocyclic portion may be aromatic, or partially or fully saturated and has 5 to 10 ring atoms in which at least 1 ring atom is a N, 0 or S atom, the alkyl portion, which is branched or unbranched, has I to 5 carbon atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 0, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof.
  45. 47. A compound according to claim 1, wherein R' is: alkyl having I to 8 carbon atoms, which is branched or unbranched and which is substituted one or more times by halogen, cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having I to 4 carbon atoms, alkoxy having I to 4 carbon atoms, or combinations thereof, or a heterocyclic group, which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least I ring atom is a N, 0 or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, 65 P:\WPIXCS\DHT1SPECI\l2513301 Mcmoy IstSPAdoc-18/09/2009 aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof.
  46. 48. A compound according to claim 47, wherein R1 is: alkyl having I to 8 carbon atoms which is substituted one or more times by halogen, or cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having I to 4 carbon atoms, alkoxy having I to 4 carbon atoms, or combinations thereof.
  47. 49. A compound according to claim 48, wherein R' is cycloalkyl having 3 to 10 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having I to 4 carbon atoms, alkoxy having I to 4 carbon atoms, or combinations thereof.
  48. 50. A compound according to claim 49, wherein R' is cycloalkyl having 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having I to 4 carbon atoms, alkoxy having I to 4 carbon atoms, or combinations thereof.
  49. 51. A compound according to claim 50, wherein R' is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
  50. 52. A compound according to claim 51, wherein R' is cyclopentyl.
  51. 53. A composition according to claim 16, further comprising another pharmaceutical agent selected from other PDE4 inhibitors, calcium channel blockers, cholinergic drugs, adenosine receptor modulators, ampakines, NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors.
  52. 54. A compound of the formula II, as defined in claim 1, substantially as herein described with reference to the Examples. 66 P:\WPDOCS\DImSPEChlI 2513301 Manory IsISPA.doc.- 109/2009
  53. 55. Use of a compound according to any one of claims 1-15 or 54, in the manufacture of a medicament for effecting PDE4 enzyme inhibition, enhancing cognition and/or treating psychosis.
  54. 56. Use of a compound according to any one of claims 1-15 or 54, in the manufacture of a medicament for treating a patient having a disease involving decreased cAMP levels.
  55. 57. Use of a compound according to any one of claims 1-15 or 54, in the manufacture of a medicament for treating a patient suffering from an allergic or inflammatory disease.
  56. 58. Use of a compound according to any one of claims 1-15 or 54, in the manufacture of a medicament for treating a patient suffering from neurodegeneration resulting from a disease or injury.
  57. 59. Use of a compound according to any one of claims 1-15 or 54, in the manufacture of a medicament for treating a patient suffering from drug addiction or morphine dependence. 67
AU2003256601A 2002-07-19 2003-07-18 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors Ceased AU2003256601B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010200233A AU2010200233A1 (en) 2002-07-19 2010-01-21 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39672602P 2002-07-19 2002-07-19
US60/396,726 2002-07-19
PCT/US2003/022401 WO2004009557A1 (en) 2002-07-19 2003-07-18 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010200233A Division AU2010200233A1 (en) 2002-07-19 2010-01-21 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Publications (2)

Publication Number Publication Date
AU2003256601A1 AU2003256601A1 (en) 2004-02-09
AU2003256601B2 true AU2003256601B2 (en) 2009-10-29

Family

ID=30770939

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003256601A Ceased AU2003256601B2 (en) 2002-07-19 2003-07-18 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
AU2010200233A Abandoned AU2010200233A1 (en) 2002-07-19 2010-01-21 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010200233A Abandoned AU2010200233A1 (en) 2002-07-19 2010-01-21 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Country Status (20)

Country Link
US (2) US7655802B2 (en)
EP (1) EP1549619B1 (en)
JP (1) JP2006502995A (en)
CN (2) CN100381425C (en)
AT (1) ATE421505T1 (en)
AU (2) AU2003256601B2 (en)
BR (1) BR0313000A (en)
CA (1) CA2492911A1 (en)
CO (1) CO5680420A2 (en)
DE (1) DE60325984D1 (en)
ES (1) ES2323688T3 (en)
HK (1) HK1081194A1 (en)
HR (1) HRP20050082A2 (en)
IL (1) IL166164A0 (en)
MX (1) MXPA05000825A (en)
NO (1) NO20050871L (en)
NZ (1) NZ537725A (en)
RU (1) RU2354648C2 (en)
WO (1) WO2004009557A1 (en)
ZA (1) ZA200500436B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
CA2609429A1 (en) * 2005-05-31 2006-12-07 Boehringer Ingelheim International Gmbh Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
PL1981851T3 (en) 2006-01-31 2012-07-31 Array Biopharma Inc Kinase inhibitors and methods of use thereof
JP5517935B2 (en) * 2007-08-17 2014-06-11 エルジー・ライフ・サイエンシーズ・リミテッド Indole and indazole compounds as cell necrosis inhibitors
US8665272B2 (en) * 2007-09-26 2014-03-04 Autodesk, Inc. Navigation system for a 3D virtual scene
JP2011504885A (en) * 2007-11-30 2011-02-17 戚 郁芬 Antidepressants prepared from salmon cyclic adenosine monophosphate
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20150065191A (en) * 2012-11-08 2015-06-12 화이자 인코포레이티드 Heteroaromatic compounds and their use as dopamine d1 ligands
EP3137454A1 (en) * 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000868A1 (en) * 1995-06-21 1997-01-09 Sanofi 4-phenylaminothiazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
WO1998009961A1 (en) * 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
JP2001011047A (en) * 1999-06-28 2001-01-16 Nikken Chem Co Ltd Phosphodiesterase inhibitor
AU2002246723B2 (en) * 2000-12-21 2005-07-14 Novartis Ag Pyrimidineamines as angiogenesis modulators

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE580519C (en) * 1932-02-26 1933-07-12 I G Farbenindustrie Akt Ges Process for the preparation of 2-oxy-3-arylaminonaphthalenes
US3259623A (en) 1963-06-14 1966-07-05 Olin Mathieson Process for preparing 2-(secondary amino)-halogenopyrimidines
GB1337389A (en) 1969-12-10 1973-11-14 Ici Ltd Pyrimidine derivatives
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2244520B1 (en) 1973-07-06 1977-02-04 Ugine Kuhlmann
US4524373A (en) 1982-02-24 1985-06-18 Kanzaki Paper Manufacturing Co., Ltd. Fluoran derivatives as new compounds, process for preparing the same and recording system utilizing the same as colorless chromogenic material
GB2202434B (en) * 1987-03-25 1990-03-28 Tachi S Co Apparatus for manufacturing a seat
US5221682A (en) * 1989-06-28 1993-06-22 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarylamino- and heteroaryloxypyridinamines and related compounds
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5204226A (en) 1991-03-04 1993-04-20 International Business Machines Corporation Photosensitizers for polysilanes
US5204366A (en) 1991-06-10 1993-04-20 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US6096768A (en) * 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
CA2114114C (en) 1992-06-15 2005-05-03 Nigel Robert Arnold Beeley Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
DK0652868T3 (en) 1992-07-28 2005-02-14 Aventis Pharma Ltd Inhibitors of c-AMP phosphodiesterase
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
TW263495B (en) 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0700389A1 (en) 1993-05-27 1996-03-13 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
ES2176252T3 (en) * 1993-07-02 2002-12-01 Altana Pharma Ag BENZAMIDS REPLACED WITH FLUORO-ALCOXI AND ITS USE AS INHIBITING AGENTS OF PHOSPHODIESTERASES OF CYCLIC NUCLEOTIDES.
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
JPH07206789A (en) 1993-09-01 1995-08-08 Taisho Pharmaceut Co Ltd Production of combretastatin analog compound
KR960704855A (en) 1993-10-12 1996-10-09 돈 엠. 커. 1N-Alkyl-N-arylpyrimidinamines and derivatives thereof
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
DE69433594T2 (en) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough TRISUBSTITUTED PHENYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS PHOSPHODIESTERASE (TYPE IV) INHIBITORS
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
FR2729142A1 (en) 1995-01-06 1996-07-12 Smithkline Beecham Lab New heterocyclic amine derivs.
US5731477A (en) 1995-01-31 1998-03-24 Smithkline Beecham Corporation Method for synthesis of aryl difluoromethyl ethers
IT1275433B (en) 1995-05-19 1997-08-07 Smithkline Beecham Farma DIARYLDIAMINE DERIVATIVES
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9603723D0 (en) * 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
ES2201299T3 (en) * 1996-06-25 2004-03-16 Pfizer Inc. INDAZOL SUBSTITUTED DERIVATIVES AND ITS USE AS TYPE IV PHOSPHODIESTERASE (PDE) INHIBITORS AND TUMOR NECROSIS FACTOR (TNF) `.
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
US6235736B1 (en) 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
US5919937A (en) * 1997-10-29 1999-07-06 Merck & Co., Inc. Process for phosphodiesterase IV inhibitors
ES2195419T3 (en) * 1997-11-25 2003-12-01 Warner Lambert Co BENCENOSULFONAMIDE INHIBITORS OF PDE-IV AND THERAPEUTIC USE.
WO1999033806A1 (en) 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
JP3542482B2 (en) 1997-12-25 2004-07-14 日研化学株式会社 3-anilino-2-cycloalkenone derivatives
EP1117659B1 (en) * 1998-09-29 2003-12-03 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6180650B1 (en) 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
GB2350110A (en) * 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofurans
ES2258459T3 (en) 1999-05-21 2006-09-01 Bristol-Myers Squibb Company PINROLOTRIAZINAS INHIBIDORAS DE QUINASAS.
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
MXPA02003436A (en) 1999-10-07 2002-08-20 Amgen Inc Triazine kinase inhibitors.
EP1235804A1 (en) * 1999-11-27 2002-09-04 Dong Wha Pharmaceutical Industrial Co. Ltd. Novel 3-nitropyridine derivatives and the pharmaceutical compositions containing said derivatives
ES2254077T3 (en) 1999-12-18 2006-06-16 Wella Aktiengesellschaft DERIVATIVES 2-AMINOALQUIL-1,4-DIAMINOBENCENO AND ITS USE FOR DYING FIBERS.
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US6699890B2 (en) * 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
SK9152003A3 (en) 2001-01-22 2004-04-06 Memory Pharm Corp Aniline derivatives useful as phosphodiesterase 4 inhibitors
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US20030149052A1 (en) 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7405230B2 (en) 2002-07-19 2008-07-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
CN100513397C (en) 2002-11-19 2009-07-15 记忆药物公司 Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000868A1 (en) * 1995-06-21 1997-01-09 Sanofi 4-phenylaminothiazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
WO1998009961A1 (en) * 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
JP2001011047A (en) * 1999-06-28 2001-01-16 Nikken Chem Co Ltd Phosphodiesterase inhibitor
AU2002246723B2 (en) * 2000-12-21 2005-07-14 Novartis Ag Pyrimidineamines as angiogenesis modulators

Also Published As

Publication number Publication date
JP2006502995A (en) 2006-01-26
CN100381425C (en) 2008-04-16
US20100093806A1 (en) 2010-04-15
EP1549619B1 (en) 2009-01-21
HRP20050082A2 (en) 2005-06-30
RU2354648C2 (en) 2009-05-10
DE60325984D1 (en) 2009-03-12
AU2010200233A1 (en) 2010-02-11
CA2492911A1 (en) 2004-01-29
ES2323688T3 (en) 2009-07-23
ATE421505T1 (en) 2009-02-15
CN1668602A (en) 2005-09-14
CN101423497A (en) 2009-05-06
US20070123570A1 (en) 2007-05-31
BR0313000A (en) 2005-07-12
NO20050871L (en) 2005-02-18
MXPA05000825A (en) 2005-08-29
ZA200500436B (en) 2006-07-26
RU2005104820A (en) 2005-10-10
EP1549619A1 (en) 2005-07-06
NZ537725A (en) 2006-08-31
WO2004009557A1 (en) 2004-01-29
AU2003256601A1 (en) 2004-02-09
US7655802B2 (en) 2010-02-02
CO5680420A2 (en) 2006-09-29
HK1081194A1 (en) 2006-05-12
IL166164A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
EP1692109B1 (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
US7700631B2 (en) Phosphodiesterase 4 inhibitors
US7655802B2 (en) Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
AU2002313673B2 (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors
EP1435944B1 (en) 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
AU2002303078B2 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
EP1888528A2 (en) Phosphodiesterase 4 inhibitors
US7153871B2 (en) Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) Phosphodiesterase 4 inhibitors
NZ547469A (en) 6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
KR20050019902A (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired